잠시만 기다려 주세요. 로딩중입니다.

Repositioning medication for cardiovascular and cerebrovascular disease to delay the onset and prevent progression of Alzheimer’s disease

Archives of Pharmacal Research 2020년 43권 9호 p.932 ~ 960
김희영, 김은영,
소속 상세정보
김희영 ( Lee Hee-Young ) - Konyang University Department of Clinical Medicinal Sciences
김은영 ( Kim Eun-Young ) - Chung-Ang University College of Pharmacy

Abstract


Alzheimer’s disease (AD) is a complex, progressive, neurodegenerative disorder. As with other common chronic diseases, multiple risk factors contribute to the onset and progression of AD. Many researchers have evaluated the epidemiologic and pathophysiological association between AD, cardiovascular diseases (CVDs), and cerebrovascular diseases (CBVDs), including commonly reported risk factors such as diabetes, hypertension, and dyslipidemia. Relevant therapies of CVDs/CBVDs for the attenuation of AD have also been empirically investigated. Considering the challenges of new drug development, in terms of cost and time, multifactorial approaches such as therapeutic repositioning of CVD/CBVD medication should be explored to delay the onset and progression of AD. Thus, in this review, we discuss our current understanding of the association between cardiovascular risk factors and AD, as revealed by clinical and non-clinical studies, as well as the therapeutic implications of CVD/CBVD medication that may attenuate AD. Furthermore, we discuss future directions by evaluating ongoing trials in the field.

키워드

Alzheimer's disease; Cardiovascular disease; Cerebrovascular disease; Pharmacotherapeutic implications; Drug repositioning

원문 및 링크아웃 정보

등재저널 정보

SCI(E)
MEDLINE
KCI